1. G. Poblete-Freundt, P. Kubicki-Frings, S. Glück, et al - Physicians ...

Peer Review Manuscripts:1. G. Poblete-Freundt, P. Kubicki-Frings, S. Glück, et al: Pharmacologicmodulation of the allergic histamine release from isolated guinea pig mastcells. Allergologica et Immunpathologica, 1976, 4:194-195.2. T. Ruzicka and S. Glück: Skin content and enzymatic degradation ofhistamine in atopic dermatitis. Arch Derm Res, 1980, 267:196-197.3. C. B. Mohr, S. Glück, A. Erichsen: Allergy history questionnaires. AnnAllergy, 1981, 46:47-48.4. T. Ruzicka, G. Goerz, L. Ebert, S. Glück: Therapeutische Moeglichkeitendes DADPS bei Erythematodes und bei einigen Vaskulitisformen. DerHautarzt, 1981, 32:467.5. T. Ruzicka, A. Bauer, S. Glück, M. Born: Effects of dapsone on passivearthus reaction and chemotaxis in phagocytosis of polymorphonuclearleucocytes. Arch Derm Res, 1981, 270:347-351.6. C. B. Mohr, S. Bonorden, S. Glück: Indikation zu Hausbesuchen imOrganisierten Notdienst. Notfallmedizin, 1981, 7:1035-1036.7. S. Glück, T. Ruzicka: Releasability of histamine from the skin in atopicdermatitis. Arch Derm Res, 1981, 268:239-240.8. C. P. Mohr, M. Hagedorn, S. Glück, S. Bonorden: Der Notdienst, z. B.Bonn. Rh. Aerzteblatt, 1983, 13:669-670.9. S. Bonorden, N. Roewer, S. Glück, C. P. Mohr: Indikationen zuHausbesuchen. Muenchner Med Wschr, 1983, 125:529-530.10. W. Schmutzler, S. Glück, M. Huber, B. Fischer, P. Pult: Is cholinergichistamine release a mechanism of allergy or pseudo-allergy? MonogrAllergy, 1983, 18:186-189.11. S. Glück, H. Merck, W. Sterry, G. Goerz, W. Schneider: ErhoehteAdenosin-Desaminase-Aktivitaet bei Patienten mit Mycosis fungoides. DerHautarzt, 1983, 34:337-338.12. T. Ruzicka, S. Glück: Cutaneous histamine levels and histaminereleasability from the skin in atopic dermatitis and hyper-IgE-syndrome.Arch Derm Res, 1983, 275:41-44.13. W. Schmutzler, K. Delmich, D. Eichelberg, S. Glück: The humanadenoidal mast cell. Susceptibility to different secretagogues andsecretion inhibitors. Int Arch Allergy appl Immunology, 1985, 77:177-178.

14. D. Peest, H. J. Schmoll, I. Schedel, H. Deicher, J. Boll, U. Essers, H.Gamm, S. Glück et al: Current results of a multicenter trial in multiplemyeloma. Onkologie, 1986, 9:168-169.15. B. Melnik, S. Glück, R. M. Jungblut, G. Goerz: Retrospective radiologicstudy of skeletal changes after long term etretinate therapy. Br J Derm,1987, 116:207-212.16. D. Peest, H. J. Schmoll, I. Schedel, S. Glück, K. Schuhmacher, H.Deicher: VBAMDex chemotherapy in advanced multiple myeloma. Eur JHaematology, 1988, 40:245-249.17. P. Heering, R. Meschig, S. Glück, W. Kreussel, G. Plewig, B. Grabensee:Kaposi-Sarkom nach Nierentransplantation. Dtsch Med Wschr, 1989,114:1407-1410.18. G. Haidl, S. Glück, S. Melnik, G. Goerz: Nicht vergessen: Bleivergiftung.Dermatosen in Beruf und Umwelt, 1989, 37:206-209.19. D. Söhngen, W. Köster, B. M. E. Kuntz, S. Glück, W. Schneider: Threecases of acquired factor VIII: C inhibitors in nonhaemophilic patients. KlinWochenschr, 1990, 68:1071-1075.20. S. Glück, W. Köster: IAP in malignant diseases: clinical relevance?Cancer, 1991, 67:610-612.21. S. Glück, W. Köster, W. Schneider: Immunelektrophorese vs.Immunfixation: Diagnostische Relevanz? Tumor Diagnostik Therapie,1991, 12:13-15.22. K. Sebok, D. Woodside, A. Al-Aoukaty, A. Ho, S. Glück, A. Maghazachi:IL-8 Induces the Locomotion of Human IL-2-Activated Natural Killer Cells.J of Immunol, 1993, 150:1524-1534.23. D. Ho, S. Glück, C. Germond, C. Sinoff, G. Dietz, M. Maruyama, R. E. T.Corringham: Optimal Timing for Collections of Blood Progenitor CellsFollowing Induction Chemotherapy and Granulocyte-Macrophage Colony-Stimulating Factor for Autologous Transplantation in Advanced BreastCancer. Leukemia, 1993, 11:1738-1746.24. D. Peest, R. Coldewey, H. Deicher, M. Sailer, C. Vykoupil, R. Leo, A.Georgii, J. Karow, E. Hoeppner, V. Diehl, U. Essers, H. Gamm, S. Glücket al: Prognostic Value of Clinical, Laboratory, and HistologicalCharacteristics in Multiple Myeloma: Improved Definition of Risk Groups.Eur J Cancer, 1993, 29A:978-983.

25. S. Glück, Jake Van Dyk, Hans A. Messner: Radiosensitivity of humanclonogenic myeloma cells and normal bone marrow precursors: Effect ofdifferent dose rates and fractionation. Int J Rad Onco Biol Physics, 1994,Vol.28(4):877-882.26. Anthony D. Ho, M. Maruyama, A. Maghazachi, J. Mason, S. Glück, R.E.T.Corringham: Soluble CD4, Soluble CD8, Soluble CD25, lymphopoieticrecovery, and endogenous cytokines after high-dose chemotherapy andblood stem cell transplantation. Blood, 1994, Vol.84(10):3550-3557.27. Carolyn M. Mulroney, Stefan Glück, Anthony D. Ho: The use ofphotodynamic therapy in bone marrow purging. Sem in Onc, 1994, Vol.21(6):24-27.28. S. Glück, A. Gagnon: Neutropenic fever in patients after high-dosechemotherapy followed by autologous haematopoietic progenitor celltransplantation and human recombinant granulocyte-macrophage colonystimulating factor. Bone Marrow Transplant, 1994, 14:989-990.29. K. Tonkin, S. Glück, M. Trudeau, T. Vandenberg: Controversies in thetreatment of metastatic breast cancer. Current Oncology, 1995, 2:87-91.30. S. Glück, Tony Chadderton, Kathy Porter, Gunter Dietz, MidoriMaruyama: Characterization and Transfusion of In Vitro CultivatedHaematopoietic Progenitor Cells. Transfus Sci, 1995, 16(3):273-281.31. S. Glück: Autologous transplantation for patients with advanced breastcancer with emphasis on bony metastasis. Canadian J of Onc, 1995,5(1):58-62.32. S. Glück: Anastrozole is superior to tamoxifen as first-line therapy inhormone receptor-positive advanced breast carconoma. Cancer, 1995,(11): 2442-244433. S. Glück: Controversy over high-dose chemotherapy. Canadian FamPhysician, 1996, 42:2834. S. Glück, A. Chadderton, A. D. Ho: The Selective Uptake and DifferentialCell Kill By Benzoporphyrin Derivative Mono-Acid Ring A On MultipleMyeloma Cells In Vitro. Photochemistry and Photobiology, 1996,63(6):846-853.35. Ross, A. A., T. J. Layton, A. M. Ostrander, J. L. Passos-Coelho, J. M.Davis, A. M. Huelskamp, S. J. Noga, N. E. Davison, M. J. Kennedy, B. W.Cooper, S. L. Gerson, H. M. Lazarus, K. Holland, S. Glück, T. J. Moss, A.Kaubish, L. Vahdat, K. Antman: Comparative Analysis of Breast Cancer

Contamination in Mobilized and Nonmobilized Haematopoietic Grafts. J ofHematotherapy, 1996, 5(5):549-552.36. O'Reilly, S. E., M. Crump, S. Glück, W. Hryniuk, L. K. Seymour: High-Dose Chemotherapy for Breast Cancer: Is the jury still out? CurrentOncology, 1996, 3(2):125-131.37. Hortobagyi G. N., L. Richard, D. O. Theriault, L. Porter, D. Blayney, A.Lipton et al: Efficacy of Pamidronate in Reducing Skeletal Complicationsin Patients With Breast Cancer and Lytic Bone Metastases. N Engl J ofMed 1996, 335(24):1785-1791. (Participation as PI).38. Fisher B, A. Brown, E. Mamounas, S. Wieand, A. Robidoux, R. G.Margolese: Effect of Preoperative Chemotherapy on Local-RegionalDisease in Women With Operable Breast Cancer: Findings From NationalSurgical Adjuvant Breast and Bowel Project B-18. J of Clin Onc 1997,15(7):2483-2493. (Participation as PI).39. S. Glück, C. Des Rochers, C. Cano, M. Dorreen, C. Germond, K. Gill, P.Lopez: High-dose chemotherapy followed by autologous blood celltransplantation: A safe and effective outpatient approach. Bone MarrowTransplantation, 1997, 6(20):431-435.40. T. Chadderton, C. Wilson, M. Bewick, and S. Glück: Evaluation of ThreeRapid RNA Extraction Reagents: Relevance for Use in RT-PCR 'S toMeasure Low Level Gene Expression in Clinical Samples. Cellular andMolecular Biol 1997, Dec, 43(8).41. S. Glück, A. A. Ross, T. J. Layton, A. B. Ostrander, L. C. Goldstein, K.Porter, A. D. Ho: Decrease in tumour cell contamination and progenitorcell yield in leukapheresis products after consecutive cycles ofchemotherapy for breast cancer. Biology of Blood and MarrowTransplantation, 1997, 3:316-323.42. Z. Wang, S. Glück, L. Zhang, M. Moran: Requirement for PCL-rlenzymatic activity in growth factor-induced mutagenesis. Molecular andCellular Biol, 1998, 18:590-597.43. M. Crump, S. Glück, K. Pritchard, L. Shepherd, J. Pater: High-DoseChemotherapy with Autologous Hematopoietic Stem-Cell Support forBreast Cancer in North America. J of Clin Onc, 1998, 16(2):800-801.44. G. Hortobagyi, R. Theriault, A. Lipton, L. Porter, D. Blayney et al: Long-Term Prevention of Skeletal Complications of Metastatic Breast CancerWith Pamidronate. J of Clin Onc, 1998, 16(6):2038-2044. (Participation asNEORCC's PI).

45. S. Glück, C. Germond, P. Lopez, Cano P, M. Dorreen, T. Koski, A.Arnold, H. Dulude, G. Gallant: High-Dose Paclitaxel, Cyclophosphamideand Mitoxantrone Followed by Autologous Blood Stem Cell Support forthe Treatment of Metastatic Breast Cancer: A Phase I Trial. EuropeanJournal of Cancer 1998, 34(7):1008-1014.46. J. Gagnon, K. Porter, D. Guerin, S. Glück: Bacterial Decontamination ofBlood Stem Cell Apheresis Product. Journal of Clinical Apheresis,1998,13:103-107.47. J. Yau, C. Germond, S. Glück et al: Mitoxantrone, Prednimustine, andVincristine for Elderly Patients with Aggressive Non-Hodgkin’s Lymphoma.American Journal of Hematology, 1998, 59: 156-160.48. R.L. Theiault, A. Lipton, G.N. Hortobagyi, R. Leff, S. Glück, et. al.Pamidronate Reduces Skeletal Morbidity in Women with Advanced BreastCancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial.Journal of Clinical Oncology, 1999, Vol. 17, No 3(March):846-854.49. M. Bewick, T. Chadderton, S. Glück: Expression of C-erbB-2/HER-2 inPatients With Metastatic Breast Cancer Undergoing High-DoseChemotherapy and Autologous Blood Stem Cell Support. Bone MarrowTransplantation 1999, 24: 377 – 384.50. A.M. Parissenti, B.R. Gannon, D.J. Villeneuve, A.F. Kirwan-Rhude, A.Chadderton, S Glück: Lack of Modulation of MDR1 Gene Expression byDominant Inhibition of cAMP-dependent Protein Kinase in DoxorubicinresistantMCF-7 Breast Cancer Cells. Int. J. Cancer 1999, 82:893-900.51. P. Goss, A.K. Stewart, F. Couture, R. Klasa, S. Glück, L. Kaizer, R.Burkes, D. Charpentier, M. Palmer, L. Tye, H. Dulude: Combined Resultsof Two Phase II Studies of Taxol® (Paclitaxel) in Patients with Relapsedor Refractory Lymphomas. Leukemia and Lymphoma 1999, 34(3-4):295-304.52. S. Glück: Ex Vivo Expansion of Hematopoietic Stem Cells. Letter-to-the-Editor. Journal of Hematotherapy & Stem Cell Research. 8:575, 1999.53. A. Parissenti, B. Gannon, A. Rhude, A. Chadderton, D. Villeneuve, S.Glück: Significant Reversal of Adriamycin Resistance in Adriamycin-Resistant MCF-7 Breast Cancer Cells by Dominant Inhibition of cAMP-Dependent Protein Kinase. in press, Breast Cancer Research andTreatment, 1999.54. Stefan Glück, Douglas Stewart: What’s happening? Current status of highdose chemotherapy in breast cancer. Transfusion Science, 1999, 21:211-

214.55. I.Chin Yee, G. Browman, S. Wong, R. Esmail, R. Meyer, H. Abu Zahra, M.Crump, D. Dhaliwal, P. Galbraith, S. Glück, M. Gospodarowicz, L.Heubsch, K. Imrie, L. Kaizer, J. Matthews, J. Meharchand, H. Messner, C.Sawka, A. Smith, and I. Walker: The Role of Fludarabine in IntermediateandHigh-risk Chronic Lymphocytic Leukaemia. Current Oncology, 6(2):90-102, 2000.56. A. Chadderton, D.J. Villeneuve, S. Glück, A.F. Kirwan-Rhude, B.R.Gannon, D.E. Blais, A.M. Parissenti: Role of specific apoptotic pathwaysin the restoration of paclitaxel-induced apoptosis by valspodarindoxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res.Treat., 59:231-244, 2000.57. S. Glück, D. Stewart: Current Status of High Dose Chemotherapy inBreast Cancer. Przeglad Lekarski 2000, 57(1):30-32.58. DA Stewart, D Guo, J Luider, I Auer, J Klassen, D Morris, A Chaudhry, CBrown, JA Fl, S. Glück: The CD34 + 90 + cell dose does not predict earlyengraftment of autologous blood stem cells as well as the total CD34 + celldose. Bone Marrow Transplantation 2000, 25:435-440.59. G. Rock, E. Chin-Yee, G. Cantin, A. Giulivi, S. Glück, A. Keating, M.Keeny, J. Klassen, R. Sutherland, and the Canadian Apheresis Group andCanadian Bone Marrow Transplant Group: Quality assurance ofprogenitor cell content of apheresis products: a comparison of clonogenicassays and CD34 + enumeration. Transfusion Medicine 2000, 10:67-75.60. S. Glück and D. Stewart: High-dose therapy in breast cancer: out of favorbut not out of promise. Bone Marrow Transplantation 2000, 25:1017-1019.61. DA Stewart, D Guo, S Glück, D Morris, A Chaudhry, C deMetz, J KlassenCB Brown and FA Russell. Double high-dose therapy for Hodgkin’sdisease with dose-intensive cyclophosphamide, etoposide, and cisplatin(DICEP) prior to high-dose melphalan and autologous stem celltransplantation. Bone Marrow Transplantation 2000, 26:383-388.62. AD Schimmer, S. Jamal, H Messner, A. Keating, J. Meharchand, LHuebsch, I Walker, A Benger, S Glück, and A Smith for the Ontario BMTNetwork, Ontario, Canada. Allogeneic or autologous bone marrowtransplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of aprovincial strategy. Bone Marrow Transplantation 2000, 26:859-864.63. PR Duggan, D Guo, J Luider, I Auer, J Klassen, A Chaudhry, D Morrie, S.Glück, CB Brown, FA Russell and DA Stewart: Predictive factors for long-

term engraftment of autologous blood stem cells. Bone MarrowTransplantation 2000, 26: 1299-1304.64. Syme R.M., and S. Glück. Generation of Dendritic Cells: Role andCytokines and Potential Clinical Applications. Transfusion and ApheresisScience 2001, 24/2:117-124.65. Linda Carlson and S. Glück. Quality of life of patients treated with HDCTand ABMT in a phase I-II study. Bone Marrow Transplantation 2001,27:989-998.66. Syme R.M., and S. Glück. Effects of cytokines on the culture anddifferentiation of dendritic cells in vitro. Journal of Hematotherapy & StemCell Research 2001, 10:43-51.67. Bewick, M., Conlon, M., Gerard, S., Lee, H., Parissenti, A. M., Zhang, L.,Glück, S. , and Lafrenie, R. M. (2001) HER-2 expression is a prognosticfactor in patients with metastatic breast cancer treated with a combinationof high-dose cyclophosphamide, mitoxantrone, paclitaxel, and autologousblood stem cell support. Bone Marrow Transplantation 27: 847-853.68. G. Kassam, M. Kwon, C-S Yoon, K.S. Graham, M.K. Young, S. Glück,D.M. Waisman: Purification and characterization of A 61 : An angiostatin-likeplasminogen fragment produced by plasmin autodigestion in the absenceof sulfhydryl donors. J. Biol. Chem. 2001, 276:8924-8933.69. A. Buzdar, J. Douma, N. Davidson, R. Eledge, M. Morgan, R. Smith, L.Porter, J. Nabholtz, X. Xiang, C. Brady, and Letrozole International TrialGroup: Phase III, muilticentre, double-blind, randomized study ofLetrozole, an aromatase inhibitor, for advanced breast cancer versusmegestrol acetate (Participation as PI). J. Clin. Oncol. 2001, 19(14):3357-3366.70. R. M. Syme, P. Duggan, D. Stewart, and S. Glück. Cutting EdgeCommunication—Generation of Dendritic Cells Ex Vivo: Differences inSteady State versus Mobilized Blood from Patients with Breast Cancer,and Lymphoma and Normal Donors. Journal of Hematotherapy & StemCell Research, 2001, 10:621-630.71. Syme R.M., T. Bryan, and S. Glück. Dendritic cell based therapy: Areview focusing on antigenic selection. Journal of Hematotherapy & StemCell Research, 2001, 10:601-608.72. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, Brown CB,Chaudhry A, Glück S., Russell JA. Progenitor cell mobilisation. The CD3-16+56_NK cell count independently predicts autologous blood stem cell

mobilisation. Bone Marrow Transplant 2001; 27:1237-1243.73. S. Glück. The Worldwide Perspective in the Adjuvant Treatment ofPrimary Lymph Node Positive Breast Cancer. Breast Cancer, 2001;8(4):321-328.74. M. Bewick, M. Conlon, A.M. Parissenti, H. Lee, L. Zhang, S. Glück, andR.M. LaFrenie. Soluble Fas (CD95) is a prognostic factor in patients withmetastatic breast cancer undergoing high dose chemotherapy andautologous stem cell transplantation. Journal of Hematotherapy & StemCell Research, 2001, 10:759-768.75. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, Chaudhry A,Brown C, Glück S., Russell JA. A low CD34+ cell dose predicts relapseand death early following autologous blood stem cell transplantation.Hematology, 2001 (in press).76. S. Glück, C. Friedenreich. Clinical Approaches to Male Breast Cancer.Geriatrics and Aging, 2002, 5 (3):19-21.77. M. Bewick, M. Conlon, T. Koski, H. Lee, A.M. Parissenti, R.M. Lafrenie,S.Glück: HER-2 expression is an independent prognostic factor inpatients with metastatic breast cancer treated with a combination of highdosecyclophosphamide, mitoxantrone and paclitaxel and autologousblood stem cell support. Bone Marrow Transplantation, 2001, 27(8): 847-853.78. S. Glück. The expanding role of Epirubicin in the treatment of breastcancer. Cancer control. 2002, 9(2): 16-27.79. K. Imrie, R. Esmail, R. Meyer and the Members of the HematologyDisease Site Group of the Cancer Care Ontario Practice GuidelinesInitiative. The role of high-dose chemotherapy and stem-celltransplantation in patients with mulitple myeloma: A practice guideline ofthe Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med.2002; 136:619-629.80. R. Syme, D. Callaghan, P. Duggan, S. Bitner, J. Wolff, D. Stewart, S.Glück. Storage of blood for in vitro generation of dendritic cells. Journal ofCytotherapy, 2002, 4 (3): 271-276.81. S. Glück. How lifespan affects Medicine. Letter-To-The-Editor. Physicians’Chronicle. Journal of Medical Knowledge Management, 2002.82. M. Crump, S. Couban, R. Meyer, L. Rudinskas, B. Zanke, S. Glück, A.Maksymiuk, P. Hoskins, S. Matthews, E. Eisenhauer. Phase II Study of

Sequential Topotecan and Etoposide in Patients with Intermediate GradeNon-Hodgkin’s Lymphoma: A National Cancer Institute of Canada ClinicalTrials Group Study. Leukemia and Lymphoma, 2002, 43 (8): 1581-1587.83. J. A. Russell, H. T. Tran, D. Quinlan, A. Chaudhry, P. Duggan, C. Brown,D. Stewart, J. D. Ruether, D. Morris, S. Glück, E. Gyonyor, and B. S.Andersson. Once daily Intravenous Busulfan Given with Fludarabine asConditioning for Allogeneic Stem Cell Transplantation: Study ofPharmakokinetics and Early Clinical Outcomes. Biology of Blood andMarrow Transplantation, 2002; 8:468-476.84. D Jenkins, L DiFrancesco, A Chaudhry, D. Morris, S. Glück, A Jones, RWoodman, CB Brown, J Russell, DA Stewart. Post-transplantComplications. Successful Treatment of Post-TransplantLymphoproliferative Disorder in Autologous Blood Stem Cell TransplantRecipients. Bone Marrow Transplantation, 2002; 30: 321-326.85. S. Glück: Anastrozole is superior to tamoxifen as first-line therapy inhormone receptor-positive advanced breast cancer. Cancer, 2002,95(11):2442-2444.86. P. Duggan, K. Booth, A. Chaudhry, D. Stewart, J. D. Ruether, S. Glück,D. Morris, C. B . Brown, B. Herbut, M. Coppes, R. Anderson, J. Wolff, M.Egeler, S. Desai, A. R. Turner, L. Larratt, E. Gyonyor, J. A. Russell forAlberta Blood and Bone Marrow Transplant Program. Unrelated DonorTransplants. Unrelated Donor BMT Recipients Given Pretransplant Low-Dose Antithymocyte Globulin have Outcomes Equivalent To MatchedSibling BMT: A Matched Pair Analysis. Bone Marrow Transplantation,2002, 30:681-686.87. R. Syme, D. Stewart, M. Rodriguez-Galvez, J Luider, Y. Auer, J Klassen,D. Morris, C. Brown, J. Russell, S. Glück. Micro-Metastases in ApheresisProducts Predict Shorter Progression-Free and Overall Survival inPatients with Breast Cancer Undergoing High- Dose Chemotherapy(HDCT) and Autologous Blood Stem Cell Transplantation (ABSCT). BoneMarrow Transplantation, 2003, 32:307-311.88. T Cheng, P Forsyth, D Morris, S. Glück, C Brown, JA Russell and DAStewart. Results of high-dose chemotherapy followed by autologous stemcell transplantation without radiation in 5 patients with primary CNSlymphoma associated with poor prognostic features. Bone MarrowTransplantation, 2003, 31:679-685.89. S. Glück, M. Crump, D. Stewart, M. Levine, K. Pritchard, P. Kirkbride, J.Dancey, S. O’Reilly, T. Shore, S. couban, C. Girouard, H. Abuzara, S.Marlin, L. Shepherd. National Cancer Institute of Canada Clinical Trials

Groups, Kingston, Ontario, Canada. A randomized trial of high-dosechemotherapy (HDCT) with autologous peripheral blood stem cell support(ASCT) compared to standard chemo therapy (CT) in women withmetastatic breast cancer: A National Cancer Institute of Canada (NCIC)Clinical Trials Group Study.90. PR Duggan, A. Chaudhry, K. Booth, C. Brown, D. Stewart, JD. Ruether,D. Morris, S. Glück, MJ. Coppes, R. Anderson, J. Wolff, M. Egeler, JA.Russel. Acute graft versus host disease and early transplant relatedmortality in unrelated bone marrow transplant recipients given pretransplantrabbit anti-thymocyte globulin. Bone Marrow Transplantation25:100 (2000).91. Glück, S., R.M. Syme, M. Bewick and D. Stewart. 2003. C-erb-2/HER-2overexpression in breast cancer - prognostic significance and target fortherapy. (Submitted to Biology of Blood and Marrow Transplantation).92. R. Syme, R. Bajwa, L. Robertson, D. Stewart and S. Glück. Comparisonof CD34 and Monocyte Derived Dendritic Cells from Mobilized PeripheralBlood. Journal Hematotherapy & Stem Cell Research 2003.93. R. Syme, T. Bryan, P. Duggan, R. Bajwa, D. Stewart and S. Glück. 2004.Priming with Dendritic Cells Can Generate Strong Cytotoxic T-CellResponses To Chronic Myelogenous Leukemia (CML) Cells In Vitro. StemCells and Development 13:211-221 (2004).94. R. Syme, M. Bewick, D. Stewart, K. Porter, T. Chadderton, S. Glück. TheRole of Depletion of Dimethy Sulfoxide before Autografting: OnHematologic Recovery, Side Effects, and Toxicity. Biology of Blood andMarrow Transplantation. 10: 135-141 (2004).95. Kangarloo SB, Gangopadhyay SB, Syme RM, Wolff JEA, Glück S.Influence of Mesna on the Pharmacokinetics of Cisplatin and Carboplatinin Pediatric Cancer Patients. Medical Oncology, 2003: vol. 21 (1): 9-20.96. M. Bewick, M. Conlon, H. Lee, A.M. Parissenti, L. Zhang, S. Glück, andR.M. Lafrenie. Evaluation of sICAM-1, sVcam-1, and sE-Selectin Levelsin Patients with Metastatic Breast Cancer Receiving High-DoseChemotherapy. Stem Cells and Development 13:281-294 (2004).97. S. B. Kangarloo, S. B. Gangopadhyay, S. Glück, and J. E.A. Wolff.Bioassay for determination of Cisplatin activity in serum and urine.Turkish Journal of Cancer 34(2): 71-74, 2004.98. Syme, R., Bajwa, R., Robertson, L., Stewart, D., Glück, S. Comparison ofCD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral

Blood from Cancer Patients. Stem Cells 23:74-81, 2005.99. B. Leyland-Jones, V. Semiglazov, M. Pawlicki et al S. Glück. MaintainingNormal Hemoglobin Levels with Epoetin Alfa in Mainly NonanemicPatients with Metastatic Breast Cancer Receiving First-LineChemotherapy: A Survival Study. J Clin Oncol, Vol. 23:5960-5972,September 1, 2005.100. S. Glück. Changing the gold standard in adjuvant therapy for breastcancer: from Tamoxifen to Aromatase inhibition. Biomedicine &Pharmacotherapy 59:S321-S322, 2005.http://france.elsevier.com/direct/BIOPHA101. S. Glück et al. Metronomic therapy in recurrent and Metastatic chemoresistantSCCHN: data from a pilot study. Tom Baker Cancer Center,University of Calgary, Calgary, Alta., Canada. Biomedicine &Pharmacotherapy 59:S317-S320, 2005.102. S. Glück. Adjuvant Chemotherapy for Early Breast Cancer: Optimal Useof Epirubicin. The Oncologist. 10: 780-791, 2005.103. Don Yee, John Hanson, Harold Lau, Jodi Siever, Stefan Glück.Treatment of nasopharyngeal carcinoma in the modern era: analysis ofoutcomes and toxicity from a single centre in a non-endemic area. TheCancer Journal; 12:147-154, 2005.104. S. Glück. New Advances in the Management of Metastatic BreastCancer. JNCCN 2005; 3:S12-S16.105. Harold Lau, Sony Brar, Desiree Hao, Jack MacKinnon, Don Yee, StefanGlück. Concomitant Low-Dose Cisplatin and Three-DimensionalConformal Radiotherapy for Locally Advanced Squamous Cell Carcinomaof the Head and Neck: Analysis of Survival and Toxicity. Head & Neck28:189-196, 2006.106. Brad M. Unryn, Desiree Hao, Stefan Glück, and Karl T. Riabowol.Acceleration of Telomere Loss by Chemotherapy is greater in OlderPatients with Locally Advanced Head and Neck. Clin Cancer Res 2006;12(21).107. Richard Van Der Jagt, K. Sue Robinson, Andrew Belch, Elizabeth Yetisir,George Wells, Loree Larratt, Chaim Shustik, Stefan Glück, Keith Stewart,David Sheridan. Sequential response-adapted induction andconsolidation regimens idarubicin/cytarabine and mitoxantrone/etoposidein adult acute myelogenous leukemia: 10 year follow-up of a study by the

Canadian Leukemia Studies Group. Leukemia & Lymphoma, April 2006;47(4): 697-706.108. Michael H. Antoni, Aisha Kazi, Suzanne C. Lechner, Sarah R. Wimberly,Tammy Sifre, Kenya R. Urcuyo, Kristin Phillips, Stefan Glück, andCharles S. Carver. How Stress Management Improves Quality of LifeAfter Treatment for Breast Cancer. Journal of Consulting and ClinicalPsychology, 74(6):1143-1152, 2006.109. Gilberto Lopes, Teresa DeCesare, Giselle Ghurani, Vladimir Vincek,Merce Jorda, Stefan Glück, Orlando Silva. Primary Ectopic BreastCancer Presenting as Vulvar Mass. Journal of Clinical Breast Cancer.Volume 7: 278-279.110. Christopher Lobo, Gilberto Lopes, Orlando Silva, and Stefan Glück.Paclitaxel albumin-bound particles (AbraxaneTM) in combination withBevacizumab with or without gemcitabine: Early experience at theUniversity of Miami/Braman Family Breast Cancer Institute. Biomedicine& Pharmacotherapy, 6: 531 – 533, 2007.111. Stefan Glück. The Prevention and Management of Distant Metastases inWomen with Breast Cancer. Cancer Investigation, 25:6-13, 2007.112. Michael Crump and Stefan Glück [PI and First Authors], Dongsheng Tu,Doug Stewart, Mark N Levine, Peter Kirkbride, Janet E Dancey, SusanO’Reilly, Tshiporah Shore, Stephen Couban, Caroline Girouard, SusanMarlin, Lois E Shepherd, Kathleen I Pritchard. A randomized Trial ofHigh-dose Chemotherapy in Women with Metastatic Breast Cancer. JClin Oncol, 26:1, 37 – 43, 2008.113. Aurelio Castrellón, and Stefan Glück. Increasing the Therapeutic Indexof Traditional Chemotherapeutics with New Formulations and inCombination with Biologic Agents in Breast Cancer. Biol Therapy ofBreast Cancer. 8:3 – 7, 2007114. David M. Brizel, Barbara A. Murphy, David I. Rosenthal, Kishan J.Pandya, S. Glück, Herbert E. Brizel, Ruby F. Meredith, Dietmar Berger,Mon-Gy Chen, and William Mendenhall. Phase II Study of Palifermin andConcurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma.J Clin Oncol 26(15): 2489 – 2496, May 20, 2008.115. S. Glück and Aurelio B Castrellón. Chemoprevention of Breast Cancer.Expert Reviews: Anticancer Therapy. 8(3): 443 – 452, 2008.116. S. Glück. Invited Commentary upon “Multicenter Phase II Trial ofNeoadjuvant Therapy with Trastuzumab, Docetaxel, and Carboplatin for

Human Epidermal Growth Factor Receptor-2 – Overexpressing Stage II orIII Breast Cancer: Results of the GETN(A)-1 Trial”. Breast Diseases: AYear Book® Quarterly. Vol. 19 No. 1, 2008.117. Orlando Silva, Gilberto Lopes, Daniel Morgenzstern, Christopher Lobo,Philomena Doliny, Edgardo Santos, Sakher Abdullah, Umang Gautam,Isildinha Reis, Catherine Welsh, Joyce Slingerland, Judith Hurley, andStefan Glück. A Phase II Trial of Split, Low-Dense Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-LineTreatment of Patients with HER2/neu-Negative Metastatic Breast Cancer.Clinical Breast Cancer. Vol. 8(2). April 2008.Books, Chapters, and other publications:1. S. Glück, H. Brüster, H. Lommel, U. Merten, K. Norpoth: Merkblatt zurAIDS-Problematik. KV-Mitteilungen, 1987, 12:1-8.2. S. Glück: Grundkurs Immunologie. 24 slides with text (Diathek). 1988.3. S. Glück, W. Koester, B. Roshop, W. Schneider: Immunofixation versusimmuno-electrophoresis: diagnostic relevance. pp 261-264 In: J Radl, B.van Camp Monoclonal Gammapathies II, Clinical significance and basicmechanisms. Topics in aging research in Europe, 1989.4. S. Glück: Grundkurs Immunologie. 24 slides with text (Diathek). 1988.5. S. Glück. Stem Cell Transplantation. Breast Cancer News, Toronto,Ontario, Canada. 1996, 6-7.6. S. Glück, C. Germond, P. Lopez, P. Cano, M. Dorreen, A. Arnold, H.Dulude, G. Gallant: High-Dose Cyclophosphamide (CTX), Mitoxantrone(MXT) and Paclitaxel (Taxol®, TXL) For the Treatment of MetastaticBreast Cancer With Autologous Blood Cell (ABC) Support. AutologousMarrow and Blood Transplantation (Proc of the 8th InternationalSymposium, Arlington, Texas), 1997, 267-275.7. S. Glück, A. A. Ross, T. J. Layton, A. B. Ostrander, L. C. Goldstein, K.Porter, A. D. Ho: Detection of Breast Cancer Cells in The ApheresisProduct: Potential Clinical Significance. Autologous Marrow and BloodTransplantation (Proc of the 8th International Symposium, Arlington,Texas), 1997, 295-303.8. S. Glück, M. Crump, G.R. Bociek, D. Stewart, and Members of NCIC-CTG Group: High-dose Chemotherapy with Autologous Blood Stem CellTransplantation: Increasing Evidence for Efficacy in Patients withMetastatic Breast Cancer. Autologous Blood and Marrow Transplantation

(Proc of the 9th International Symposium, Arlington, Texas), 1999, 290-302.9. M. Bewick, T. Chadderton, M. Conlon, R. Lafrenie, D. Stewart, D. Morris,S. Glück: Expression of C-ErbB-2/Her-2 in Patients with Metastatic BreastCancer Undergoing High-dose Chemotherapy and Autologous BloodStem Cell Support. Autologous Blood and Marrow Transplantation (Procof the 9th International Symposium, Arlington, Texas), 1999, 362-374.10. S. Glück, M. Crump, D. Stewart, A. Arnold, S. Couban, P. Kirkbride, M.Levine, S. O’Reilly, K. Pritchard, A. Smith, D. Tu, J. Dansey, S. Marlin, L.Shepherd and Members of NCI-C CTG Group. Summary of CurrentStudies in Breast Cancer Using High-dose Chemotherapy and AutologousBlood Cell Transplantation, Including NCI-C CTG MA.16. AutologousBlood and Marrow Transplantation (Proc of the 10th InternationalSymposium, Dallas, Texas), July 2000, 106-112.11. Contributing author: S. Glück. Day by Day: Side by Side. University ofCalgary, Toronto, Ontario, Canada 2002.12. Stefan Glück, Rachel Syme, and Douglas Stewart. Metastatic BreastCancer: Final Verdict for High-Dose Chemotherapy. Chapter 4: SolidTumors in Stem Cell and Targeted Therapy from Proceedings of theEleventh International ABMT Symposium in Arlington, TX. December2002.13. S. Glück. Hematopoietic Growth Factor Support in Breast Cancer. J-M.Nabholtz, K. Tonkin, M. Aapro, A. Buzdar and D. Reese (Editors)“Application of Clinical and Translational Evidence to Patient Care,Second Edition. Lippincott Williams & Wilkins (pub), 2003, 447-456.14. S. Glück. Adjuvant Chemotherapy for Early Breast Cancer. The Role ofAnthracyclines and Taxanes with Increasing Dose and Dose Density inTreatment Perspecives in Solid Tumor Chemotherapy. First Asia PacificOncology Summit, Hanoi, Vietnam. Oct. 24-26, 2003: 4-5.15. S. Glück. Newer Anti-Aromatase Agents for Hormone Receptor-PositiveBreast Cancer in Treatment Perspecives in Solid Tumor Chemotherapy.First Asia Pacific Oncology Summit, Hanoi, Vietnam. Oct. 24-26, 2003: 8.16. Editorial – Reflection and reaction: Breast cancer trial with erythropoietinterminated unexpectedly. The Lancet Oncology, 2003:4, 459-460.17. S. Glück. New Developments in Hormonal Therapy. Current Status ofChemotherapy in Breast Cancer: Epirubicin/Taxane Combinations. 2003;Seoul, South Korea.

18. S. Glück. Adjuvant Therapy Update — Results from the MA.5 and FASG05 Trials. Anthracyclines, Anti-Aromatase Agents, and COX-2 Inhibitors inBreast Cancer Therapy: A Critical Appraisal by Key Opinion Leaders hasbeen made possible by an educational grant from Pfizer Oncology. March2004: p. 15-23.19. S. Glück. NOCR (Network for Oncology Communication and Research).Adjuvant Therapy Update–Results from the MA.5 and FASG 05 Trials.March 2004: p. 15-19.20. S. Glück; J. Berry, C. Bunnel, C. Geyer, C. Henderson, P. Munster.NOCR (Network for Oncology Communication and Research). AdjuvantChemotherapy-Integration of Epirubicin. March 2004. p. 27-29.21. S. Glück. Chapter 21. Adjuvant Chemotherapy for Breast Cancer inBreast Cancer: A practical Guide. 3 rd edition. p. 254-289. Editors E. O.Silva, S. Zurrida, 2005.22. S. Glück. Chapter 22. Adjuvant Endocrine Therapy in Pre- andPostmenopausal Women in Breast Cancer: A practical Guide. 3 rd edition.p. 290-308. Editors E. O. Silva, S. Zurrida, 2005.23. S. Glück. Chapter 25. Endocrine Therapy for Metastatic Breast Cancer:A practical Guide. 3 rd edition. p. 348-372. Editors E. O. Silva, S. Zurrida,2005.24. S. Glück. Chapter 30. High Dose Therapy in Breast Cancer: A practicalGuide. 3 rd edition. p. 460-480. Editors E. O. Silva, S. Zurrida, 2005.25. S. Glück. The Importance of Distant Metastasis and Its Impact onSurvival Rates in Early-stage Hormone Receptor-positive Breast Cancer.p. 39-42. European Oncological Disease 2007 [Touch Briefings]. 1 issue2007.26. S. Glück. Increasing the Therapeutic Index of TraditionalChemotherapeutics with New Formulations and in Combination withBiologic Agents in Breast Cancer. Biological Therapy of Breast Cancer.Vol. 8, No. 3: August 2007.27. S. Glück. The Role of Taxanes in the Treatment of Metastatic BreastCancer. Managed Care Oncology. Quarter 1: 11-13, 2008.Abstracts—published:1. G. Poblete-Freundt, S. Glück: Comparative study on the PCA and the invitro passive anaphylaxis in mast cells and tissues of guinea pig. Naunyn

Schmiedeberg's Arch Pharmacol, 1977, 297:172.2. B. Fischer, S. Glück, W. Schmutzler, H. Behrend: Specific supersensitivityto pharmacological stimulation of immunologically primed mast cells fromvarious species. Naunyn Schmiedeberg's Arch Pharmacol, 1979, 308:52.3. S. Glück, V. Staubach, W. Schmutzler: Further studies on the nature ofthe cholinergic histamine release from mast cells. Naunyn Schmiedeberg'sArch Pharmacol, 1980, 311:542.4. S. Glück, W. Schneider: Erhoehte Adenosin-Desaminase Aktivitaet beiPatienten mit malignen non-Hodgkin-Lymphomen. Int Welt, 1980, 55:125.5. S. Glück, W. D. Schoppe, W. Schneider: Storage of blood and isolatedlymphocytes before analysis with monoclonal antibodies. Blut, 1985,51:187.6. S. Glück, B. Melnik, G. Goerz: Retrospective evaluation of skeletalradiographic changes after long term etretinate therapy. Arch Derm Res,1986.7. D. Peest, H. J. Schmoll, I. Schedel, H. Deicher, I. Boll, U. Essers, H.Gamm, S. Glück et al: MP versus VCMP: A prospective randomized trialin stage II and III multiple myeloma. J Cancer Res and Clin Oncology,1986, 111:12.8. S. Glück, H. Worth, V. Burstedde, W. Schneider: Distribution ofmononuclear cells in bronchoalveolar lavage (BAL) and in peripheralblood in patients suffering from acquired immune deficiency syndrome(AIDS). Blut, 1986, 53:176-177.9. S. Glück, W. Schneider: Analysis of lymphocyte subsets in patients withchronic autoimmune thrombocytopenic purpura. Blut, 1986, 53:170-171.10. S. Glück, W. D. Schoppe, W. Schneider: Vincristine, cyclophosphamide,melphalan and prednisone (VCMP) chemotherapy of multiple myelomaafter ineffective melphalan and prednisone (MP) therapy. Blut, 1986,53:227.11. S. Glück, W. Schneider: Analysis of lymphocyte subsets in patients withITP. Haemostasis, 1986, 16:61.12. S. Glück, W. D. Schoppe, W. Schneider: Die VCMP Kombinations-Chemotherapie des multiplen Myeloms nach Versagen der MP-Kombinationstherapie. Med Welt, 1986, 51:1555.

13. S. Glück, W. Koester, W. Schneider: Therapeutisches Konzept beiThrombozytopenie und HIV-Infekt. Med Welt, 1987, 66:1712.14. A. Wehmeier, R. Von Kries, S. Glück, G. Goerz, W. Schneider:Hautamyloidose -seltene Erstmanifestationen eines multiplen Myeloms.Med Welt, 1987, 66:1628.15. S. Glück, K. Ebeling, H. Chlebowsky, W. D. Schoppe, W. Schneider:Kombinationschemotherapie bei Patienten mit fortgeschrittenem multiplenMyelom und Niereninsuffizienz. Med Welt, 1987, 66:1628.16. C. Hagen-Aukamp, S. Glück, W. D. Schoppe, W. Schneider: Subileus -eine seltene Komplikation der Vinblastin-Chemotherapie? Med Welt,1987, 66:1631.17. S. Glück, W. Koester, I. Spall, W. Schneider: In vitro immunologicalstudies in patients suffering from chronic lymphocytic leukaemia (B-CLL)and frequent infections. Blut, 1987, 55:299.18. C. Aul, U. Heyll, R. E. Scharf, S. Glück, W. Schneider: Chronicmyelomonocytic leukaemia evolving to acute mixed-lineage leukaemia.Blut, 1987, 55:309.19. S. Glück, R. Meschig, B. Roshop, G. Plewig, W. Schneider: First resultsof the chronic lymphocytic leukaemia treatment by extracorporealphotophoresis. Blut, 1987, 55:329.20. S. Glück: Retrospective study on eight patients treated with etretinate.Retinoids Today and Tomorrow, 1988, 10:7.21. S. Glück, D. Peest, G. Umbach, H. Deicher: Chemotherapy of multiplemyeloma: results of a multicenter trial. Proc ASCO, 1988, 7:231.22. R. Meschig, S. Glück, B. Roshop, U. Petersheim: Extracorporealphotophoresetherapie bei chronisch lymphatischer Leukaemie. Zbl HautundGeschlechskrkh, 1988, 154:623.23. S. Glück, B. Melnik, G. Goerz: Knochenveraenderungen unterRetinoidtherapie. Zbl Haut-und Geschlechtskrkh, 1988, 154:579.24. B. Roshop, S. Glück, R. Meschig, W. Koester, G. Plewig: In vitroimmunological studies in patients with cutaneous T-cell lymphoma andextracorporeal photophoresis. Blut, 1988, 57:265.25. S. Glück, W. Koester, B. Roshop, W. Schneider: Immunosuppressiveacidic protein: clinical relevance? Blut, 1988, 57:273.

26. W. Koester, B. Roshop, S. Glück, W. Schneider: Immunofixation versusimmuno-electrophoresis: diagnostic relevance? Blut, 1988, 57:277.27. S. Glück, B. Melnik, G. Goerz: Knochenveraenderungen unterRetinoidtherapie. Der Hautarzt, 1988, 39:229.28. H. H. Wolf, S. Glück, W. Schneider: Common variable immune deficiencyin adult patients. Blut, 1989, 59:280.29. D. Soehngen, W. Koester, B. M. E. Kuntz, S. Glück, W. Schneider: Threecases of acquired inhibitors against factor VIII:C. Blut, 1989, 59:307.30. W. Koester, S. Glück, W. Schneider: IgD multiple myeloma. Blut, 1989,59:325.31. W. Koester, S. Glück, B. Kutkuhn: Diagnostik und Therapie beim BenceJones Myelom. Med Welt, 1990, 72:177.32. S. Glück, J. v. Dyk, H. A. Messner: Radiosensitivity of human myelomacell lines and normal bone marrow: comparison of two different doserates. Blut, 1990, 61:150.33. S. Glück, W. Schnutenhaus, W. Schneider: Prophylactic intravenousimmunglobuline (IVIG) application to patients with recurrent infections andsecondary antibody deficiency due to B-cell neoplasia. Blut, 1990, 61:140.34. S. Glück, J. v. Dyk, H.A. Messner: Interleukin 6 enhances theradiosensitivity of myeloma cell lines.Proc AACR, 1991, 32:446.35. S. Glück, J. v. Dyk, H. A. Messner: Interleukin 6 and GM-CSF enhancesthe radiosensitivity of myeloma cell lines. Onkologie, 1991, 14-2:155.36. U. Seifert, S. Glück, H. A. Messner: Granulocyte-macrophage colonystimulating factor supports the proliferation of human myeloma cell lines.Onkologie, 1991, 153:438.37. A. Ho, C. Germond, C. Sinoff, S. Glück et al: Mobilization of peripheralstem cells for autologous transplantation by induction chemotherapycombined with GM-CSF in patients with metastatic breast cancer. ProcASCO, 1992, 11:78.38. S. Glück, J. Van Dyk, H. Messner: Radiosensitivity of human clonogenicmyeloma cells and normal bone marrow progenitors: effect of dose rateand fractionation. Proc ASCO, 1992, 11:359.

39. S. Glück, U. Seifert, X. Piao, M.D. Minden et al: Granulocyte macrophagecolony stimulating factor (GM-CSF) promotes growth of myeloma celllines. Proc AACR, 1992, 33:78.40. A. Ho, A. Maghazachi, C. Sinoff, S. Glück et al: Reconstitution of Tlymphocyte function after super-dose chemotherapy and GM-CSFmobilized peripheral stem cells. Proc AACR, 1992, 33:243.41. A. Ho, S. Glück, C. Sinoff, C. Germond, R.E.T. Corringham: Superdosechemotherapy with peripheral stem cell transplantation for patients withmetastatic breast cancer. Experimental Haematology, 1992, 20:748.42. A. A. Maghazachi, A. Al-Aoukaty, K. Sebok, D. Woodside, S. Glück andA. Ho: GM-CSF activates various intracellular signalling pathways, andinduces the expression of IL-2 R (p75) in human T lymphocytes. J ofLeukocyte Biology, 1992, Suppl. 3:51.43. K. Sebok, D. Woodside, A. Al-Aoukaty, A. Ho, S. Glück and A.Maghazachi: Evidence implicating interaction of IL-8 receptor withpertussis toxin-sensitive GTP binding protein in the induction oflocomotion in human IL-2-activated natural killer (IANK) cells. J ofLeukocyte Biology, 1992, Suppl. 3:51.44. S. Glück, T. Chadderton, A. Maghazachi, A. Ho: In vitro responses tophotodynamic treatment: Different effects on haematologic progenitorcells or cell lines derived from malignant tumours. Blood, 1992,80(10):523a.45. A. Ho, M. Maruyama, A. Maghazachi, G. Dietz, S. Glück, R. Haas, RETCorringham: Immunologic reconstitution and cytokine levels afterautologous stem cell transplants and lymphocyte subpopulations in stemcell autografts. Blood, 1992, 80(10):525a.46. A. Ho, S. Glück, C. Germond, C. Sinoff, A. Mazzuchin, RET Corringham:Optimal conditions for collection of peripheral stem cells for autologoustransplantation. Blood, 1992, 80(10):525a.47. S. Glück, T. Chadderton, A. Maghazachi, A.D. Ho: In vitro responses tophotodynamic treatment: Selective uptake and cell death byBenzoporphyrin Derivative Mono-Acid Ring A (BPD-MA). Proc AACR,1993, 34:357.48. S. Glück, K. Porter, G. Dietz, T. Chadderton, M. Maruyama: Autologousleukocyte transfusion in patients after high-dose chemotherapy andperipheral stem cell transplantation for metastatic breast cancer. ProcASCO, 1993, 12:109.

49. J. Yau, C. Germond, S. Glück, C. Cripps, S. Verma, and G. Goss:Mitoxantrone, Prednimustine, and Vincristine (NSO) induction therapy inelderly patients with poor prognosis non-Hodgkin's lymphoma. ProcASCO, 1993, 12:374.50. S. Glück, K. Porter, G. Dietz, T. Chadderton: Transfusion of in vitroexpanded and maturated haematopoietic progenitor cells. BiennialMeeting of the International Assoc. for Breast Cancer Research, 1993,Banff, Alberta.51. C. DesRochers, A. Hostrawser, V. Canning, T. Koski, C. Germond, C.Sinoff, A.D. Ho, S. Glück: High-dose chemotherapy with peripheral stemcell transplantation in patients with metastatic breast cancer. BiennialMeeting of the International Assoc. for Breast Cancer Research, 1993,Banff, Alberta.52. S. Glück, J.M. Nabholtz, P. Fargeot, G. MacLean et al: High-dosechemotherapy (HDCT) with stem cell support in metastatic breast cancer(MBC): Role of autologous peripheral blood stem cell transplantation(PBSCT) and cytokines. Breast Cancer Research, 1993, 27:183.53. J.M. Nabholtz, S. Glück: High-dose chemotherapy (HDCT) withmitoxantrone, cyclophosphamide, vinblastine or carboplatin with bonemarrow support in metastatic breast cancer (MBC): Role of autologousperipheral blood stem cell transplantation (PBSCT) and cytokines.European J of Cancer, 1993, Vol.29A(6):S.83.54. C.M. Mulroney, S. Glück, A.D. Ho: The use of photodynamic therapy inbone marrow purging. Pro of a Satellite Symposium: 62nd AnnualMeeting of the Royal College of Physicians and Surgeons of Canada.September 11, 1993 .55. S. Glück, K. Porter, T. Chadderton et al: Depletion of DMSO(Dimethylsulfoxide) prior to autografting after high-dose chemotherapy formetastatic breast cancer. Blood, 1993, 82(10)1:430a.56. C. Germond, J. Yau, G. Goss, S. Glück et al: Treatment of aggressivenon-Hodgkin's lymphoma in the elderly with Mitoxantrone, Prednimustineand Vincristine (NSO). Blood, 1993, 82(10)1.1:504a.57. S. Glück, J. Lebkowski, K. Porter et al: Characterization and transfusionof In vitro expanded haematopoietic progenitor cells. ExperimentalHaematology, 1993, 21(8):1141.58. T. Chadderton, G. Dietz, K. Porter & S. Glück: Preferential uptake of the

photosensitiser benzoporphyrin derivative mono-acid ring a by multiplemyeloma cells results in selective cell death. IV International Workshop onMultiple Myeloma Mayo Medical Centre, Rochester, Minnesota USA,October 1993. P-13.59. R. Sorrenti, T. Chadderton, S. Glück et al: Purging of minimal residualdisease from autografts with the photosensitizer benzoporphyrin derivativemonoacid ring A (BPD-MA). Keystone Symposia on Molecular & CellularBiology J of Cellular Biochemistry, 1994, Suppl. 18B:59.60. S. Glück, N. Sharan, T. Chadderton et al: In vitro combination of paclitaxel(Taxol®, TXL) with 5 different cytotoxic drugs: effect on three different celllines. Proc AACR 1994, 35:335.61. A. Lutynski, H. Atkins, S. Glück et al: Some aspects of radiosensitivity ofthe myeloid leukaemic cell lines. Proc AACR 1994, 35:335.62. K. Sebok, D. Villeneuve, G. Dietz, S. Glück: Evidence implicating thepresence of Interleukin-8 (IL-8) receptors on Human Interleukin-2 (IL-2)activated natural killer (IANK) cells.Proc AACR 1994, 35:528.63. V. Canning, A. Hostrawser, C. DesRochers, B. Kaitila, S. Glück: Theexpanded role of the apheresis nurse within the stem cell programme. 5thInt. Congress of the World Apheresis Assoc. 1994, 17.64. S. Glück, K. Porter, G. Dietz et al: Apheresis yield of haematopoieticprogenitor/stem cells using different growth factors (GF). 5th Int. Congressof the World Apheresis Assoc. 1994, 22.65. S. Glück, K. Porter, G. Dietz et al: Apheresis yield of haematopoieticprogenitor/stem cells using two different growth factors. UCSD RecentAdvances in Haematopoietic Stem Cell Transplantation - ClinicalProgress, New Technologies and Gene Therapy. March 1994, 9.66. A. D. Ho, S. Glück, C. Germond, C. Sinoff, R.E.T. Corringham: Longtermoutcome after high-dose chemotherapy with stem cell support formetastatic breast cancer. Proc. ASCO 1994, 13:96.67. S. Glück, J. M. Nabholtz, C. Germond et al: High-dose chemotherapywith autologous bone marrow or peripheral blood stem-cell support inmetastatic breast cancer. Lancet Conference, Challenge of BreastCancer, April 1994, 68.68. A. D. Ho, M. Maruyama, A. Maghazachi, J. R. Mason, S. Glück, R.E.T.Corringham: Lymphopoietic recovery and endogenous cytokines afterhigh-dose chemotherapy and blood stem cell transplantation.

Experimental Haematology, 1994, 22(8):819.69. S. Glück, J. M. Nabholtz, A. D. Ho: High-dose chemotherapy (HDCT)with autologous peripheral blood progenitor/stem cell (PBPC) support inmetastatic breast cancer (MBC). Int. J of Onc, 1994, 5:353-420:H19.70. S. Glück, C. DesRochers, A. Gagnon, B. Kaitila: Safe and effectiveapproach to an out-patient high-dose chemotherapy and peripheral bloodprogenitor/stem cell transplantation in patients with metastatic breastcancer. Int. J of Onc, 1994, 5:353-420:H20.71. R. Van der Jagt, S. Robinson, S. Glück et al: A phase II multi-centrestudy of sequential, response-adapted induction regimensIdarubicin/Cytarabine and Mitoxantrone/Etoposide, for treatment of denovo AML. Blood, 1994, 84(10):304a.72. C. Wilson, W. Kster, G. Dietz, T. Chadderton, A Lutynski, N. Sharan, G.Gallant, H. Dulude, S. Glück: In Vitro effect of Paclitaxel in combinationwith cytotoxic agents on two different human myeloma cell lines. Blood,1994, 84(10):182a.73. S. Glück, W. Koster, N. Sharan, C. Wilson, T. Chadderton, G. Dietz, M.Bewick, A. Lutynski, G. Gallant, H. Dulude: Combination of Paclitaxel(Taxol®, TXL) with different cytotoxic drugs: Effect on different breastcancer cell lines in vitro. Breast Cancer Res and Treatment, 1994, 32:36.74. C. DesRochers, V. Canning, A. Hostrawser, B. Kaitila, S. Glück: AProgressive Collaboration for Change. Canadian Oncology NursingJournal Conference Proceedings - Part I, 8th International Conference onCancer Nursing, August 1994, Vancouver, B.C.75. M. Vincent, P. Drings, K. Burk, R. Hermann, S. Glück, P.S. Mitrou et al: APhase II Study of Continuous Oral Ifosfamide (IFOS) In Advanced Non-Small Cell (NSCLC) Lung Cancer. Proc ASCO 1995, 14:382.76. A. D. Ho, S. Glück, G. Germond, J. Mason, C. Sinoff and RETCorringham: Impact of Adjuvant Chemotherapy on the Long-TermOutcome of High-Dose Chemotherapy and Stem Cell Support ForMetastatic Breast Cancer. Proc ASCO 1995, 14:323.77. V. Canning, A. Hostrawser, C. DesRochers, B. Kaitila, K. Porter, S. Glück:Peripheral Blood Stem Cell Transplantation - An Out-Patient Approach. Jof Clin Apheresis 1995, 10(1):33.78. S. Glück, T. Chadderton, K. Porter, G. Dietz, M. Bewick, T. Koski et al:Yield of Haematopoietic Progenitor/Stem Cells and the Impact On

Haematologic Recovery After High-Dose Chemotherapy In Patients WithAdvanced Breast Cancer. J of Clin Apheresis. 1995, 10(1):36.79. S. Glück, C. DesRochers, B. Kaitila, V. Canning, A. Hostrawser: Safeand Effective Approach to an Out-Patient High-Dose Chemotherapy andPeripheral Blood Progenitor/Stem Cell Transplantation in Patients withMetastatic Breast Cancer. J of Clin Apheresis 1995, 10(1):36.80. S. Glück, A. Arnold, A.D. Ho, J. M. Nabholtz: High-Dose Chemotherapy(HDCT) With Autologous Blood Progenitor/Stem Cell (PBPC) Support InMetastatic Breast Cancer (MBC). Can J of Infectious Disease 1995,6(C):428C.81. S. Glück, A. Arnold, D. Bhatt, P. Cano, J. Chang, M. Dorreen et al: High-Dose Cyclophosphamide (CTX), Mitoxantrone (MXT), and Paclitaxel(Taxol®, TXL) For The Treatment of Metastatic Breast CA. With BloodStem Cell Support. Can J of Infectious Disease 1995, 6(C):428C.82. S. Glück, W. Koster, N. Sharan, C. Wilson, T. Chadderton, G. Dietz et al:Combination of Paclitaxel (Taxol®, TXL) with Different Cytotoxic Drugs:Effect on Malignant Cell Lines In Vitro. Can J of Infectious Disease 1995,6(C):397C.83. R. van der Jagt, S. Robinson, S. Glück, D. Sheridan, J. Mathhews, A.Blech et al: A Phase II Multi-Centre Study of Sequential, Response-Adapted Induction Regimens Idarubicin/Cytarabine andMitoxantrone/Etoposide, For Treatment of De Novo AML. Royal College ofPhysicians and Surgeons of Canada Annual Meeting Aug 1995,18(4):B62.84. T. Chadderton, G. Dietz, K. Porter, M. Bewick, A. Lutynski, S. Glück:Differential PCR (dPCR) Detection of the Her-2/Neu Oncogene InAutografts of Patients With Metastatic Breast Cancer (MBC) UndergoingBlood Stem Cell (BSC) Transplantation. Exp Hematol 1995, 22(8):762.85. S. Glück, J. M. Nabholtz, M. Crump, A. D. Ho: High-Dose Chemotherapy(HDCT) With Autologous Blood Stem Cell (BPC) Support In MetastaticBreast Cancer (MBC). Exp Hematol 1995, 22(8):754.86. S. Glück, C. Des Rochers: Blood Cell Transplantation: An OutpatientApproach. OHCEN 3rd Annual Symposium, November 1995, Toronto,Ontario, 25.87. J-M. Nabholtz, S. Glück, M. Crump, T. Al-Tweigeri, E. Sansregret, C.Germond et al: Induction Chemotherapy (ICT) Followed by Double High-Dose Polychemotherapy (HDCT) With Mitoxantrone, Cyclophosphamide,

And Vinblastine Or Carboplatin With Autologous Peripheral Blood StemCell Transplantation (Apbsct) In Metastatic Breast Cancer (Mbc). BreastCancer Res and Treatment, 1996, 37:45.88. C. E. Cumming, J-M. Nabholtz, C. A. Wentzel, M. Handman, J. Clinch, S.Glück et al: High-Dose Chemotherapy With Peripheral Blood Stem CellTransplantation In Breast Cancer: An Assessment of Quality of Life.Breast Cancer Res and Treatment, 1996, 37:47.89. S. Glück, A. Arnold, P. Cano, M. Dorreen, C. Germond, P. Lopez et al:High-Dose Cyclophosphamide (CTX) Mitoxantrone (MXT), and Paclitaxel(Taxol®, TXL) For The Treatment of Metastatic Breast Cancer With BloodCell Support. Blood Cell and Bone Marrow Transplantation. Keystone,Colorado, January 1996.90. S. Glück, A. Gagnon, K. Porter, A. Hostrawser, V. Canning: In VitroMicrobial Decontamination of Apheresis Products For Use InAutotransplantation. ASFA, Santa Fe, New Mexico 1996, 46.91. G. N. Hortobagyi, L. Porter, D. Blayney, R.L. Theriault, A. Lipton, S. Glücket al: Reduction of Skeletal Related Complications In Breast CancerPatients With Osteolytic Bone Metastases Receiving Chemotherapy (CT),By Monthly Pamidronate Sodium (PAM) (Aredia®) Infusion. Proc ASCO1996, 15:108.92. R. Theriault, A. Lipton, R. Leff, S. Glück, J. Stewart, S. Costello et al:Reduction of Skeletal Related Complications In Breast Cancer PatientsWith Osteolytic Bone Metastases Receiving Hormone Therapy, ByMonthly Pamidronate Sodium (Adredia®) Infusion. Proc ASCO 1996,15:122.93. S. Glück, A. Arnold, H. Dulude, G. Gallant: High-DoseCyclophosphamide (CTX), Mitoxantrone (MTX), And Paclitaxel (Taxol®,TXL) With Blood Progenitor Cell Support For The Treatment of MetastaticBreast Cancer. Proc ASCO 1996, 15:137.94. J-M, Nabholtz, S. Glück, M. Crump, T. Al-Tweigeri, A. Hewitt, R. Berg. APilot Phase II Study Of FAC Induction Chemotherapy Followed by TwoCourses of High Dose Poly-Chemotherapy Supported With FilgrastimMobilized Peripheral Blood Progenitor Cells (PBPC) In The First-LineTreatment of Metastatic Breast Cancer (MBC). Proc ASCO 1996, 15:147.95. P. Goss, A. Stewart, F. Couture, R. Burkes, S. Glück, L. Kaizer et al: APhase II Study Of Paclitaxel (P) In Patients With Refractory Lymphomas.Proc ASCO 1996, 15:419.

96. S. Glück, T. Chadderton, K. Porter, G. Dietz: Characterization andTransfusion of In Vitro Cultivated Haematopoietic Progenitor Cells.Transfusion Medicine 1996, 6(1):78.97. S. Glück, A. Gagnon, K. Porter, A. Hostrawser, V. Canning: In VitroMicrobial Decontamination of Apheresis Products For Use InAutotransplantation. J Clin Apheresis 1996, 11(2):100.98. M. Bewick, T. Chadderton, S. Glück: The Role of Her-2/Neu In PatientsWith Metastatic Breast Cancer Undergoing High-Dose Chemotherapy.Exp Hematol 1996, 24(9):1030.99. S. Glück, A. Arnold, P. Cano, M. Dorreen, C. Germond, P. Lopez, H.Dulude, G. Gallant: High-Dose Cyclophosphamide (CTX), Mitoxantrone(MXT), and Paclitaxel (Taxol®, TXL) For the Treatment of MetastaticBreast Cancer With Blood Cell Support. Int J of Hematology 199664(1):S153.100. S. Glück, A. D. Ho: High Dose Chemotherapy (HDCT) with AutologousBlood Cell (BC) Support in Metastatic Breast Cancer (MBC). Eur J ofCancer 1996, 32A(2):35.101. S. Glück, A. Arnold, P. Cano, M. Dorreen, C. Germond, P. Lopez, H.Dulude, G. Gallant: High-Dose Cyclophosphamide (CTX), Mitoxantrone(MXT), and Paclitaxel (Taxol®, TXL) for the Treatment of MetastaticBreast Cancer (MBC) with Blood Cell Support. Eur J of Cancer 1996,32A(2):37.102. R. Theriault, A. Lipton, R. Leff, S. Glück, J. Stewart, S. Costello et al:Reduction of Skeletal Related Complications in Breast Cancer Patientswith Osteoloytic Bone Metastases Receiving Hormone Therapy , byMonthly Pamidronate Sodium (Aredia®) Infusion. Eur J of Cancer 1996,32A(2):50.103. G. N. Hortobagyi, L. Porter, D. Blayney, R. L. Theriault, A. Lipton, S.Glück, H. Wheeler, S. Allan, J. Simeone, J. Seaman, R. Knight, M.Heffeman, D. Reitsma: Reduction of Skeletal Related Complications inBreast Cancer Patients with Osteolytic Bone Metastases ReceivingChemotherapy (CT), by Monthly Pamidronate Sodium (PAM) (Aredia®)Infusion. Eur J of Cancer 1996, 32A (2):50.104. T. Chadderton, M. Bewick, C. Wilson, S. Glück: RNA Purification FromFresh and Cryopreserved Bone Marrow, Peripheral Blood and ApheresisProducts: Comparison of Three Commercially Available Methods.Cellular& Molecular Biology 1996, 42:S-114.

105. S. Glück, P. Cano, M. Dorreen, C. Germond, P. Lopez, A. Arnold, H.Dulude, G. Gallant: High-Dose Cyclophosphamide (CTX), Mitoxantrone(MXT), and Paclitaxel (Taxol®, TXL) For the Treatment of MetastaticBreast Cancer With Stem Cell Support. Breast Cancer Res andTreatment, 1996, 41(3):277.106. A. A. Ross, A. A., T. J. Layton, A. M. Ostrander, J. L. Passos-Coelho, J.M. Davis, A. M. Huelskamp, S. J. Noga, N. E. Davison, M. J. Kennedy, B.W. Cooper, S. L. Gerson, H. M. Lazarus, K. Holland, S. Glück, T. J. Moss,A. Kaubish, L. Vahdat, K. Antman: Comparative Analysis of BreastCancer Contamination in Mobilized and Nonmobilized HaematopoieticGrafts. J of Hematotherapy, 1996, 5(5):589.107. G. Rock, P. Leblond, S. Glück, A. Keating and Members of the CAG:Peripheral blood stem cell apheresis in Canada. World ApheresisAssociation, Florence, Italy, November 1996.108. G. Rock, I. Chin-Yee, S. Glück, A. Keating, G. Cantin, A. Giulivi, J.Klassen, R. Sutherland: Multicentre comparison of assays for theenumeration of stem cells in peripheral blood stem cell apheresisproducts. American Society for Apheresis, Arlington, VA, March 1997.109. G. Rock, I. Chin-Yee, S. Glück, A. Keating, G. Cantin, A. Giulivi, J.Klassen, R. Sutherland: Multicentre comparison of assays for theenumeration of stem cells in peripheral blood stem cell apheresisproducts. J of Clin Apheresis, 1997, 12(1):23.110. S. Glück, A. A. Ross, T. J. Layton, A. B. Ostrander, L. C. Goldstein, K.Porter, A. D. Ho: Detection of breast cancer cells in the apheresis product(AP) and their potential clinical significance. Proc of ASCO 1997, 16:112a.111. A. Lipton, P. A. Hershey, R. Theriault, T. X. Houston, R. Leff, G. A.Atlanta, S. Glück: Long-term reduction of skeletal complications in breastcancer patients with osteolytic bone metastases receiving hormonetherapy, by monthly 90 mg pamidronate (Aredia®) infusions. Proc ofASCO 1997, 152a.112. G. N. Hortobagyi, L. Porter, R. L. Theriault, D. Blayney, A. Lipton, S.Glück, H. Wheeler, S. Allan, J. Simeone, J. Seaman, R. Knight, M.Hefferman, D. Reitsma, T. X. Houston, T. N. Brentwood. Long-termreduction of skeletal complications in breast cancer patients (pts) withosteolytic bone metastases receiving chemotherapy, by monthly 90 mgpamidronate (Aredia®) infusions. Proc of ASCO 1997, 151a.113. A. D. Ho, C. Germond, C. Sinoff, J. Mason, R.E.T. Corringham, S. Glück:Prognostic factors influencing outcome of autologous transplantation for

metastatic breast cancer. Proc of ASCO 1997, 94a.114. M. Bewick, T. Chadderton, S. Glück: Prognostic potential of C-erbB-2/HER2 over-expression in patients with metastatic breast cancerundergoing high-dose chemotherapy and blood stem cell transplantation.Blood 1997, 90:1029.115. J. Moreb, B. Cooper, K. Holland, C. Elliot, H.M. Lazarus, S. Glück, T. J.Moss: The prognostic value of immunocytochemical (ICC) analysis onbone marrow (BM) taken from patients with stage II/III breast cancerundergoing autologous transplant (ABMT) therapy. Blood 1997, 90:1703.116. R. van der Jagt, S. Robinson, S. Glück, A. Belch, D. Sheridan, J.Matthews, L. Larratt, S. Markman, N. Di Pietro, B. Pham, C. Shustik, K.Stewart: Response-adapted therapy of de novo acute myeloblasticleukemia (AML): Update of a Phase II multi-centre study of sequentialinduction regimens Idarubicin/Cytarabine and Mitoxantrone/Etoposide.Blood 1997, 90:2264.117. M. Bewick, T. Chadderton, S. Glück: C-erbB-2/HER2 overexpression inpatients with metastatic breast cancer undergoing high-dosechemotherapy: A prognostic factor. Breast Cancer Res and Treatment,1997, 46(1):66.118. G. Bociek, E. Reed, S. Tarantolo, S. Verma, B. Graham, S. Glück: Acomparative study of high-dosce chemotherapy/stem cell transplantation(HCSCT) versus standard chemotherapy (CT) in patients (PTS) withmetastatic breast cancer (MBC). Proc of ASCO 1998, 114a.119. T. Dearden, A. Chadderton, B. Yan, M. Bewick, A. Rhude, A. Parissenti,S. Glück: Probenecid as a potential modulator of drug resistance in theMRP overexpressing breast cancer cell line MCF7-VP. Proc of ASCO1998, 239a.120. J. M. Connors, A. Belch, A. Benger, B. Burns, S. Glück, R. Klasa, R.Meyer, A. Sandura, C. Sawka, B. Schacter, L. Shepherd, A. Smith, B.Zee: Brief VACOP-B followed by high-dose EC+A + GM-CSF for patientswith poor prognosis aggressive lymphoma. Proc of ASCO 1998, 12a.121. M. Bewick, T. Chadderton, S. Glück: C-erB-2/HER2 Overexpression inPatients with Metastatic Breast Cancer Undergoing High-DoseChemotherapy: A Prognostic Factor. Acta Haematologica 1998,100(SI)98:18, #71.122. A. Schimmer, S. Jamal, A. Smith, J. Meharchand, A. Keating, L. Huebsch,I. Walker, A. Benger, S. Glück, H. Messner: Results of a provincial

strategy for allogeneic or autologous bone marrow transplantation (BMT)as treatment of relapsed non-hodgkin’s lymphoma (NHL). J. Amer. Soc.Hematology 1998, 92(10):286a, #1174.123. D.A. Stewart, J-M. Nabholtz, P. Geggie, J.D. Ruether, P. Craighead, S.Glück, M. Smylie, J. Mackey, A.H.G. Paterson: Adjuvant and NeoadjuvantUse of High Dose Mitoxantrone, Vinblastine, Cyclophosphamide (MVC)and Autologous Stem Cell Support for Patients with Poor Prognosis StageII/III Breast Cancer (BrCa). Proceedings of ASCO 1999, 18:103a, #389.124. M. Crump, R. Meyer, S. Couban, L. Rudinskas, P. Hoskins, B. Zanke, S.Glück, A. Maksymiuk, S. Matthews, and E. Eisenhauer: Phase II Study ofTopotecan + Etoposide in Patients with Aggressive Histology Non-Hodgkin’s Lymphoma (NHL). Proceedings of 41st Annual Meeting of theAmerican Society of Hematology 1999, Journal of the American Society ofHematology 94 (10 Suppl 1):526a, #2353.125. R.H.C. Van der Jagt, K.S. Robinson, A. Belch, D.P. Sheridan, S. Glück,A.K. Stewart, L. Larratt, J. Matthews, C. Shustik, for the CanadianLeukemia Studies Group: Long term follow-up of response adapted noncrossresistant therapy for de novo AML using sequential inductionregimens idarubicin/cytarabine and mitoxantrone/etoposide. Proceedingsof 41st Annual Meeting of the American Society of Hematology 1999,Journal of the American Society of Hematology 94 (10 Suppl 1):300a,#1340.126. S. Glück, H. Falter, A. Gagnon, T. Koski, M.A. Girouard, G. Gallant, H.Dulude, H. Neorcc and Leurentian University: Pharmacokinetic (PK)analysis of high-dose paclitaxel (Taxol®, P), cyclophosphamide (CTX),mitoxantrone (MXT) with autologous blood stem cell support in metastaticbreast cancer. Proceeding of American Association for Cancer Research1999, 40:495, #3270.127. A. Chadderton, D.J. Villeneuve, S. Glück, A.M. Parissenti: Restoration ofpaclitaxel (Taxol®, P) induced chemosensitivity and apoptosis inadriamycin-resistant MCF-7 breast cancer cells by inhibition of P-glycoprotein function using SDZ-PSC833. Proceedings of AmericanAssociation of Cancer Research 1999, 40:664, #4378.128. D.H. Callaghan, R.M. Syme, S. Bitner, F.E. Wolff, S. Glück: Storage ofBlood for in vitro generation of dendritic cells. Abstracts from the TandemBMT Annual Meeting. Biology of Blood and Marrow Transplantation 2000,6:139, #19.129. M.A. Chaudhry, P. Duggan, C.B. Brown, D. Stewart, F.D. Ruether, S.Glück, D. Morris, F.A. Russell, Alberta BMT Program, Calgary, Alberta,

Canada: Myeloablative chemotherapy for allogeneic transplantation with afludarabine/busulfan protocol (Flubup): Comparison with Bucy. Abstractsfrom the Tandem BMT Annual Meeting. Biology of Blood and MarrowTransplantation 2000, 6:140, #24.130. P.R. Duggan, A. Chaudhry, D. Guo, F. Luider, I. Auer, F. Klassen, D.Morris, S. Glück, F. Russell, D. Stewart: Total CD34+ dose/kg predictslong-term outcome following autologous blood stem cell transplant(ASCT). Abstracts from the Tandem BMT Annual Meeting. Biology ofBlood and Marrow Transplantation 2000, 6:142, #37.131. D.A. Stewart, D. Guo, S. Glück, D. Morris, A. Chaudhry, F. Klassen, F.Luider, I. Auer, C. Brown, F.A. Russell: Low CD34+ cell dose is advserselyassociated with relapse-free (RFS) and overall survival )OAS) followingautologous blood stem cell transplantation (ASCT). Abstracts from theTandem BMT Annual Meeting. Biology of Blood and MarrowTransplantation 2000, 6:129, #50.132. F.A. Russell, A. Chaudhry, P. Duggan, D. Stewart, F.D. Ruether, S.Glück, D. Morris, C.B. Brown, Alberta BMT Program, Calgary, Alberta,Canada: Preliminary experience with once daily intravenous Busulfan(BU): A comparison with conventional oral BU in combination withFludarabine as conditioning for allogeneic BMT. Abstracts from theTandem BMT Annual Meeting. Biology of Blood and MarrowTransplantation 2000, 6:156, #88133. D.A. Stewart, D. Guo, S. Glück, D. Morris, A. Chaudhry, F. Klassen, C.Brown, FJA. Russell: Possible role for dose-intensive cyclophosphamide,etoposide, cisplatin (DICEP) as re-induction and stem cell mobilizationtherapy for relapsed or refractory non-Hodgkin’s lymphoma (NHL).Abstracts from the Tandem BMT Annual Meeting. Biology of Blood andMarrow Transplantation 2000, 6:159, #100.134. R.M. Syme, D.H. Callaghan, S. Bitner, D. Stewart, S. Glück: Generationof dendritic cells in vitro from patients with breast cancer, and lymphomaand normal donors: Differences in steady state versus mobilized blood.Abstracts from the Tandem BMT Annual Meeting. Biology of Blood andMarrow Transplantation 2000, 6:160, #101.135. F.A. Russell, P. Duggan, A.M. Chaudhry, D. Stewart, S. Glück, D.Ruether, D. Morris, K. Booth, M. Coopes, R. Anderson, J. Wolff, M.Egeler, C.B. Brown. Unrelated donor BMT recipients given pretransplantantithymocyte globulin have outcomes equivalent to matched sibline BMT:a matched pair analysis. Abstracts of the American Society of Hematology2000, #1788, 416a.

136. R.M. Syme, P. Duggan, T. Bryan, D. Stewart, S. Glück, D. Cultureddendritic cells can prime potent cytotoxic T lymphocyte responses tochronic myelogenous leukemia. Abstracts of the American Society ofHematology 2000, #3862, 46b.137. D.A. Stewart, D. Guo, J. Luider, I. Auer, J. Klassen, D. Morris, K.A.Valentine, C.B. Brown, A. Chaudhry, S. Glück, F.A. Russell. CD3-16+56+NK cell count independently predicts autologous blood stem cellmobilization (BSCM). Abstracts of the American Society of Hematology2000, #5127, 319b.138. F.A. Russell, A.M. Chaudhry, P. Duggan, D. Stewart, D. Ruether, D.Morris, S. Glück, C.B. Brown. Daily intravenous busulfan (BU):comparison with conventional oral BU in combination with fludarabine asconditioning for allogeneic stem cell transplant. Abstracts of the AmericanSociety of Hematology 2000, #5188, 333b.139. F.A. Russell, P. Duggan, A. Chaudhry, D. Stewart, S. Glück, D. Ruether,D. Morris, C.B. Brown. Fludarabine and busulfan (FLUBUP) plusantithymocyte globulin as conditioning for allogeneic stem cell transplant –myeloablation with relatively low early morbidity. Abstracts of theAmerican Society of Hematology 2000, #5189, 333b.140. F.A. Russell, A.M. Chaudhry, P. Duggan, D. Stewart, D. Ruether, S.Glück, D. Morris, M.J. Coppes, R. Anderson, J. Wolff, M. Egeler, K.Booth, S. Desai, L. Larratt, R. Turner, C.B. Brown. Haploidenticaltransplants using partial T-cell depletion, cyclosporin and Low-doseantithymocyte globulin as GVHD prophylasix. Abstracts of the AmericanSociety of Hematology 2000, #5326, 364b.141. S. Glück, M. Crump, D. Stewart, A. Arnold, S. Couban, P. Kirkbride, M.Levine, S. O’Reilly, K. Pritchard, A. Smith, D. Tu, J. Dansey, S. Marlin andL. Shepherd for the National Cancer Institute of Canada clinical TrialsGroup (NCI-C CTG), Canada. A randomized comparative trial of highdose chemotherapy and autologous stem cell support versus standarddose chemotherapy following response to anthracycline or taxane basedchemotherapy in women with metastatic breast cancer: NCI-C CTGMA.16. Abstracts of the Bone Marrow Transplantation, EBMT InternationalConference on High-Dose Chemotherapy in Breast and Ovarian Cancer2000, #14, S10.142. CM. Thirukkumaran, S. Lupichuck, N. Nodwell, J. Luider, S. Nishikawa, P.Forsyth, R. Johnston, D. Stewart, S. Glück, P. Lee, D. Morris: Exploitationof reovirus as a novel purging strategy in autologous stem cell transplants.Abstract from the Alberta Cancer Board Annual Meeting 2000.

143. S. Glück, R. Syme, D. Stewart: CerbB-2/HER-2 overexpression in breastcancer-prognostic significance and target for therapy. Presented at the13th International Symposium on Molecular Biology of Hematopoiesis,2000.144. R.M. Syme, D. Callaghan, D. Stewart, S. Glück: In vitro generation ofdendritic cells from normal donors and patients with breast cancer, orlymphoma: Differences in steady state versus mobilized blood. Presentedat the 13th International Symposium on Molecular Biology ofHematopoiesis 2000.145. Syme, R.M., D. Stewart and S. Glück. Cultured dendritic cells can primepotent CTL responses to a Her-2+ve breast cancer cell line. Abstracts forthe 2001 Tandem BMT Meetings, Journal of the American Society forBlood and Marrow Transplantation, 7(2):90, #100.146. S. Glück, M. Crump, D. Stewart, M. Levine, K. Pritchard, P. Kirkbride, J.Dancey, S. O’Reilly, T. Shore, S. Couban, C. Girouard, H. Abuzara, D. Tu,S. Marlin, L. Shepherd. A randomized trial of high-dose chemotherapy(HDCT) with autologous peripheral blood stem cell support (asct)compared to standard chemo therapy (ct) in women withmetastatic breastcancer: a National Cancer Institute of Canada (NCIC) clinical trials groupstudy. Abstracts from the ECCO 11 the European Cancer Conference,2001, S285, #1052.147. Syme, Rachel M, Duggan, Peter, Bryan, Tracey, Stewart, Doug, Glück,Stefan. Dendritic cells can prime potent CTL responses to CML. Abstractsfrom AACR 92nd Annual Meeting Proceedings of the AmericanAssociation for Cancer Research, 2001, 42:22, #116.148. M. Crump, S. Glück, D. Stewart, M. Levine, K. Pritchard, P. Kirkbride, J.Dancey, S. O’Reilly, T. Shore, S. Couban, C. Girouard, H. Abu-Zahra, D.Tu, S. Marlin, L. Shepherd; National Cancer Institute of Canada ClinicalTrials Group, Kingston, ON, Canada. A randomized trial of high-dosechemotherapy (HDC) with autologous peripheral blood stem cell support(ASCT) compared to standard therapy in women with metastatic breastcancer: a National Cancer Institute of Canada (NCIC) Clinical Trials GroupStudy. Abstracts from ASCO 37th Annual Meeting Proceedings of ASCO,2001, 20:21A, #82.149. P.O. Cano, C.J. Germond P.G. Lopez, S. Verma, S. Glück, EasterbrookNortheastern Ontario Regional Cancer Centre, Sudbury, ON, Canada;Ottawa Regional Cancer Centre, Ottawa, ON, Canada; Tom Baker CancerCentre, Calgary, AB, Canada; University Health Network, Toronto, ON,Canada. The use of chloroquine in metastatic melanoma. Abstracts fromASCO 37th Annual Meeting Proceedings of ASCO, 2001, 20:286b, #2895.

150. LE Abrey, CH Moskowitz, WP Mason, D. Stewart, PA Forsyth, DM Caron,LM DeAngelis; Sloan Kettering Cancer Centre, New York, NY: PrincessMargaret Hospital, Toronto, Canada; tom Baker Cancer, Calgary, AB,Canada. A phase I study of intensive methotrexate and cytarabinefollowed by high dose beam chemotherapy with autologous stem celltransplantation (ASCT) in patients with newly diagnosed primary centralnervous system lymphoma (PCNSL). Abstracts from ASCO 37th AnnualMeeting Proceedings of ASCO 2001, 20:53a, #a207.151. J.A. Russel, P. Duggan, A.M. Chaudhry, C. Fibich, D. Stewart, S. Glück,J.D. Ruether, D. Morris and C. Brown. Low dos antithymocyte globulinincorporated into GVHD prophylasix for matched related donor stem celltransplantation results in low morbidity and no mortality from acute GVHD.Abstracts from the 43rd ASH Annual Meeting, Blood. 2001. 98:11, #2773.152. J.A. Russell, H. Tran, A.M. Chaudhry, D. Stewart, S. Glück, J.D. Ruether,D. Morris, C. Brown, P. Duggan, D. Quinlan, J. Nguyen and B. Andersson.Once daily intravenous busulfan: pharmacokinetic analysis and clinicalstudy in combination with fludarabine (FLUBUP) as myeloablativeconditioning for allogeneic stem cell transplantation in 70 patients withhematologic malignancy. Abstracts from the 43rd ASH Annual Meeting,Blood. 2001. 98:11, #1995.153. JA Russell, HT Tran, AM Chaudhry, P Duggan, D Stewart, D Ruether, SGlück, D Morris, CB Brown. Once Daily Intravenous Busulfan (IVBU):Pharmacokinetic Study and Comparison with Oral Busulfan (POBU) inCombination with Fludarabine (FLU) as Conditioning for Allogeneic StemCell Transplant. Biology of Blood and Marrow Transplant. 2001. 7(2), #86.154. Syme, R.M., D. Stewart and S. Glück. Cultured dendritic cells can primepotent CTL responses to a Her-2+ve breast cancer cell line. Biology ofBlood and Marrow Transplant. 2001. 7(2):90, #100.155. Glück, S. The Worldwide Perspective in the Adjuvant Treatment ofPrimary Lymph Node Positive Breast Cancer. 9 th Annual Meeting of theJapanese Breast Cancer Society Satellite Symposium. Maebashi, Japan.June 7-8, 2001.156. Kangarloo SB, Wolff JEA, Glück S. Influence of Mesna on thepharmacokinetics of Cisplatin and Carboplatin in pediatric cancer patients.Abstracts from 38th Annual Meeting of ASCO, Journal of ClinicalOncology, 2002, 21: 121a, #482.157. M. Crump, S. Glück, A randomized trial of high-dose chemotherapy(HDCT) with autologous peripheral blood stem cell support (ASCT)

compared to standard chemotherapy (CT) in women with metastaticbreast cancer: A National Cancer Institute of Canada (NCIC) clinical trailsgroup study. Abstracts from the 2nd International Conference on HighDose Chemotherapy: Innovation and Evolution, Biology of Blood andMarrow Transplantation, 2002, pg. 338.158. T Cheng, P Forsyth, D Morris, S. Glück, C Brown, JA Russell and DAStewart. Results of high-dose chemotherapy followed by autologous stemcell transplantation without radiation in 5 patients with primary CNSlymphoma associated with poor prognostic features, Abstracts from the2nd International Conference on High Dose Chemotherapy: Innovationand Evolution, Biology of Blood and Marrow Transplantation, 2002, pg.343.159. R. Syme, M. Kelly, M. Rodriguez-Galvez, J. Luider, Y. Auer, J. Klassen, D.Morris, C. Brown, J. Russel, D. Stewart and S. Glück. Micro-metastasis Inapheresis products predict shorter progression free survival and overallsurvival in patients with breast cancer undergoing high dosechemotherapy (HDCT) and autologous blood stem cell transplantation(ABSCT). Abstracts from the 2nd International Conference on High DoseChemotherapy: Innovation and Evolution, Biology of Blood and MarrowTransplantation, 2002, pg. 346.160. Kangarloo SB, Wolff JEA, Glück S. Influence of Mesna on thepharmacokinetics of Cisplatin and Carboplatin in pediatric cancer patients.Abstracts from the 2nd International Conference on High DoseChemotherapy: Innovation and Evolution, Biology of Blood and MarrowTransplantation, 2002, pg. 344.161. DA Stewart, J-M Nabholtz, P Geggie, JD Reuther, P Craighead, AHGPaterson, M Smylie, J Mackey, S. Glück. Adjuvant and neoadjuvant useof high dose mitoxantrone, vinblastine, cyclophosphamide (MVC) andautologous stem cell transplantation (ASCT) for patients with poorprognosis stage II/III breast cancer (BrCa). Abstracts from the 2ndInternational Conference on High Dose Chemotherapy: Innovation andEvolution, Biology of Blood and Marrow Transplantation, 2002, pg. 346.162. R. Syme, M. Kelly, D. Stewart, S. Glück. Cultured dendritic cells canprime potent CTL in lymphoma. Abstracts from the 2nd InternationalConference on High Dose Chemotherapy: Innovation and Evolution,Biology of Blood and Marrow Transplantation, 2002, pg. 346.163. Christian Fibich, Douglas Stewart, Joanne Luiders, Christopher Brown,Don Morris, Stefan Glück, Ramakrishnaran Parameswaran, DianneQuinlin, Ashan Chaudry, James A. Russell. Allogeneic Stem-Cell-Tranmsplantationf or chronic lymphatic leukemia (CLL) with ATG-

containing conditioning: Evidence for improved survival and preservationof graft vx leukemia effect. Abstract of the 44th ASH Annual Meeting,2002, Blood, 100(11):212a, #798164. James A. Russell, Ashan M. Chaudry, Christian Fibich, Diana M. Quinlan,Stefan Glück, Don Morris, Christopher B. Brown, RamakrishnaranParameswaran, Douglas Stewart. Improved survival in adult matchedsibling stem cell transplant (SCT) recipients given pretransplant low-doseantithymocyte globulin (ATG): A matched pair analysis. Abstract of the44th ASH Annual Meeting, 2002, Blood, 100(11):429a, #1663.165. Rachel Syme, Ron Bajwa, Doug Stewart and Stefan Glück. CD34positive cells are a better cellular source for generating dendritic cells frommobilized peripheral blood than monocytes. 94th Annual MeetingProceedings, 2003, Proceedings of the American Association for CancerResearch, 44:414, #1825.166. Stefan Glück, J. Mackinnon, H. Lau, R. Syme, J. Dort, D. Glück,University of Calgary. Metronomic therapy in recurrent and metastaticchemo-esistant SCCHN: Data from a pilot study. 39th Annual MeetingProceedings, 2003, American Society of Clinical Oncology; p.513 #2066167. J. Dancey, M. Crump, Stefan Glück, D. Tu, S. Marlin, L. Shepherd, for theNCI Canada Clinical Trials Group. Quality of life (QOL) analysis of arandomized trial of high-dose chemotherapy (HDCT) with peripheral stemcell transplant (PSCT) versus standard chemotherapy (SCT) in womenwith metastatic breast cancer (MBC): National Cancer Institute of CanadaClinical Trials Group study (NCIC CTG) MA-16. 39th Annual MeetingProceedings, 2003, American Society of Clinical Oncology; p.749 #3010.168. Kangarloo SB, Russel JA, Andersson BS, Syme RM, Quinlan D, andGlück S. A Test Dose Strategy for Pharmacokinetically GuidedIndividualized Dosing of Intravenous Busulfan. Blood, Vol. 102 (11), Nov.16, 2003, p. 4016, Abstract #5335.169. H. Lau, D. Yee, J. Mackinnon, S. Brar, D. Hao, S. Glück. Concomitantlow-dose Cisplatin and radiotherapy for locally advanced squamous cellcarcinoma of the head and neck (SCCHN): Analysis of survival andtoxicity. 40th Annual Meeting Proceedings, 2004, American Society ofClinical Oncology; p. 500 Abstract #5555.170. D. Yee, H. Lau, J. Siever, P. Brasher, J. Mackinnon, S. Glück.Concurrent Chemotherapy (chemoRT) for nasopharyngeal carcinoma(NPC): 10-year experience at a single institute. 40th Annual MeetingProceedings, 2004, American Society of Clinical Oncology; p. 504Abstract #5573.

171. C. F. Lobo, G. Lopes, O. Silva, S. Glück. Nanoparticle album-bound(Nab) Paclitaxel (P) in combination with bevacizumab (B) with and withoutgemcitabine (G): Early experience at the Braman Family Breast CancerInstitute. American Society of Clinical Oncology; p. 504 Abstract #5573.172. O. E. Silva, G. Lopes, D. Morgensztern, C. Lobo, S. Abdullah, P. Doliny, J.Slingerland, S. Glück, E. Santos, C. Welsh, J. Hurley. Split, low-dosedocetaxel (D) and low-dose Capecitabine (C) is an active regimen inmetastatic breast cancer with minimal toxicity.173. International Oncology Network (ION)-ION Symposia in Review: SanAntonio Breast Review. New Paradigms in Adjuvant Systemic Therapyfor Early Breast Cancer. www.iononline.com. Las Vegas, NV. February10-12, 2006; p. 9-10.174. O. E. Silva, G. Lopes, D. Morgensztern, C. Lobo, S. Abdullah, P. Doliny, J.Slingerland, S. Glück, E. Santos, C. Welsh, J. Hurley. Split, low-dosedocetaxel (D) and low-dose Capecitabine (C) is an active regimen inmetastatic breast cancer with minimal toxicity. June 2-6, 2006 42 ndAnnual ASCO Meeting Proceedings. J Clin Oncol. Vol. 24:18 S part I of II;Abs #10618, June 20, 2006.175. C. F. Lobo, G. Lopes, O. Silva, and S. Glück. Nanoparticle albuminbound(Nab) paclitaxel (P) in combination with bevacizumab (B) with andwithout gemcitabine (G): Early experience at the Braman Family BreastCancer Institute. June 2-6, 2006 42 nd Annual ASCO MeetingProceedings. J Clin Oncol. Vol. 24:18 S part I of II; Abs #10748, June 20,2006.176. RS Akins, C Takita, C Gomez-Fernandez, N ElSayyad, J Nguyen, KLaFave, M Jorda, S Glück, E Avisar, and J Hurley. Metaplastic and TripleNegative Breast Carcinomas. Proceedings Intl J Rad Onc. Biol Physics2007, vol. 69 #2064 p. S238.L. Baumbach, M.E. Ahearn, M. Jorda, C. Gomez, O. Silva, T.A. Halsey, J. Yan K.Ellis